{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:50:10Z","timestamp":1793296210505,"version":"4.5.0"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec id=\"ab-noi240025-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Unilateral magnetic resonance imaging (MRI)\u2013guided focused ultrasound subthalamotomy (FUS-STN) improves cardinal motor features among patients with asymmetrical Parkinson disease (PD). The feasibility of bilateral FUS-STN is as yet unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240025-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the safety and effectiveness of staged bilateral FUS-STN to treat PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240025-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This prospective, open-label, case series study was conducted between June 18, 2019, and November 7, 2023, at HM-CINAC, Puerta del Sur University Hospital, Madrid, Spain, and included 6 patients with PD who had been treated with unilateral FUS-STN contralateral to their most affected body side and whose parkinsonism on the untreated side had progressed and was not optimally controlled with medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240025-7\">\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Staged bilateral FUS-STN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240025-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Primary outcomes were assessed 6 months after the second treatment and included safety (incidence and severity of adverse events after second treatment) and effectiveness in terms of motor change (measured with the Movement Disorders Society Unified Parkinson\u2019s Disease Rating Scale part III [MDS-UPDRS III]) in the off-medication state (ie, after at least 12 hours of antiparkinsonian drug withdrawal) compared with baseline (ie, prior to the first side ablation). Secondary outcomes included motor change in patients in the on-medication state (ie, after usual antiparkinsonian medication intake), motor complications (measured with the MDS-UPDRS IV), daily living activities (measured with the MDS-UPDRS I-II), quality of life (measured with the 39-item Parkinson\u2019s Disease Questionnaire), change in dopaminergic treatment, patient\u2019s global impression of change (measured with the Global Impression of Change [PGI-C] scale), and long-term (24-month) follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240025-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 45 patients previously treated with unilateral FUS-STN, 7 were lost to follow-up, and 4 were excluded due to adverse events. Of the remaining 34 patients, 6 (median age at first FUS-STN, 52.6 years [IQR, 49.0-57.3 years]; 3 women [50%]) experienced progression of parkinsonism on the untreated body side and were included. At the time of the first FUS-STN, patients\u2019 median duration of disease was 5.7 years (IQR, 4.7-7.3 years). The median time between procedures was 3.2 years (IQR, 1.9-3.5 years). After the second FUS-STN, 4 patients presented with contralateral choreic dyskinesia, which resolved by 3 months. Four patients developed speech disturbances, which gradually improved but remained in a mild form for 2 patients at 6 months; 1 patient experienced mild imbalance and dysphagia during the first week after treatment, which subsided by 3 months. No behavioral or cognitive disturbances were found on neuropsychological testing. For patients in the off-medication state, MDS-UPDRS III scores improved by 52.6% between baseline and 6 months after the second FUS-STN (from 37.5 [IQR, 34.2-40.0] to 20.5 [IQR, 8.7-24.0]; median difference, 23.0 [95% CI, 7.0-33.7];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.03). The second treated side improved by 64.3% (MDS-UPDRS III score, 17.0 [IQR, 16.0-19.5] prior to the second treatment vs 5.5 [IQR, 3.0-10.2]; median difference, 9.5 [95% CI, 3.2-17.7];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.02). After the second procedure, all self-reported PGI-C scores were positive.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240025-10\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings of this pilot study suggest that staged bilateral FUS-STN was safe and effective for the treatment of PD, although mild but persistent speech-related adverse events were observed among a small number of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.1220","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:01:15Z","timestamp":1715598075000},"page":"638","source":"Crossref","is-referenced-by-count":33,"title":["Staged Bilateral MRI-Guided Focused Ultrasound Subthalamotomy for Parkinson Disease"],"prefix":"10.1001","volume":"81","author":[{"given":"Ra\u00fal","family":"Mart\u00ednez-Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria HM Hospitales, Madrid, Spain"},{"name":"CIBERNED, Instituto Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Natera-Villalba","sequence":"additional","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"},{"name":"PhD Medicine Program, Universidad Aut\u00f3noma de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rodr\u00edguez-Rojas","sequence":"additional","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"},{"name":"CIBERNED, Instituto Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"del \u00c1lamo","sequence":"additional","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Pineda-Pardo","sequence":"additional","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"},{"name":"CIBERNED, Instituto Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Obeso","sequence":"additional","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqualina","family":"Guida","sequence":"additional","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Jim\u00e9nez-Castellanos","sequence":"additional","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"P\u00e9rez-Bueno","sequence":"additional","affiliation":[{"name":"Anesthesia Department, Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Duque","sequence":"additional","affiliation":[{"name":"Neuroradiology Department, Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge U.","family":"Ma\u00f1ez-Mir\u00f3","sequence":"additional","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"},{"name":"now with Department of Neurology, Hospital Vithas 9 de Octubre, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gasca-Salas","sequence":"additional","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"},{"name":"CIBERNED, Instituto Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Matarazzo","sequence":"additional","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"},{"name":"CIBERNED, Instituto Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Alonso-Frech","sequence":"additional","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Obeso","sequence":"additional","affiliation":[{"name":"HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria HM Hospitales, Madrid, Spain"},{"name":"CIBERNED, Instituto Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"noi240025r1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1474-4422(17)30403-9","article-title":"Focused ultrasound subthalamotomy in patients with asymmetric Parkinson\u2019s disease: a pilot study.","volume":"17","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2018","journal-title":"Lancet Neurol"},{"issue":"26","key":"noi240025r2","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1056\/NEJMoa2016311","article-title":"Randomized trial of focused ultrasound subthalamotomy for Parkinson\u2019s disease.","volume":"383","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"noi240025r3","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease.","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"noi240025r4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/jnnp.71.5.611","article-title":"Bilateral pallidotomy for treatment of Parkinson\u2019s disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation.","volume":"71","author":"Merello","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"noi240025r5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/mds.v32.1","article-title":"Speech and language adverse effects after thalamotomy and deep brain stimulation in patients with movement disorders: a meta-analysis.","volume":"32","author":"Alomar","year":"2017","journal-title":"Mov Disord"},{"issue":"1","key":"noi240025r6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/mdc3.12004","article-title":"STN vs GPi deep brain stimulation: translating the rematch into clinical practice.","volume":"1","author":"Williams","year":"2014","journal-title":"Mov Disord Clin Pract"},{"issue":"9","key":"noi240025r7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp-2020-325278","article-title":"Bilateral staged magnetic resonance\u2013guided focused ultrasound thalamotomy for the treatment of essential tremor: a case series study.","volume":"92","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"noi240025r8","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1002\/mds.v36.11","article-title":"Bilateral focused ultrasound thalamotomy for essential tremor (BEST-FUS phase 2 trial).","volume":"36","author":"Iorio-Morin","year":"2021","journal-title":"Mov Disord"},{"issue":"5","key":"noi240025r9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/mdc3.v9.5","article-title":"Bilateral focused ultrasound pallidotomy for Parkinson-related facial dyskinesia\u2014a case report.","volume":"9","author":"Stieglitz","year":"2022","journal-title":"Mov Disord Clin Pract"},{"issue":"3","key":"noi240025r10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases.","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"noi240025r11","doi-asserted-by":"publisher","first-page":"i5239","DOI":"10.1136\/bmj.i5239","article-title":"CONSORT 2010 statement: extension to randomised pilot and feasibility trials.","volume":"355","author":"Eldridge","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"noi240025r12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mdc3.v7.3","article-title":"Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide.","volume":"7","author":"Schade","year":"2020","journal-title":"Mov Disord Clin Pract"},{"issue":"5","key":"noi240025r13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/mds.v33.5","article-title":"Neurological adverse event profile of magnetic resonance imaging\u2013guided focused ultrasound thalamotomy for essential tremor.","volume":"33","author":"Fishman","year":"2018","journal-title":"Mov Disord"},{"issue":"pt 3","key":"noi240025r14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/brain\/awh397","article-title":"Bilateral subthalamotomy in Parkinson\u2019s disease: initial and long-term response.","volume":"128","author":"Alvarez","year":"2005","journal-title":"Brain"},{"issue":"1","key":"noi240025r15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1212\/WNL.0b013e318203e7d0","article-title":"Effects of subthalamic stimulation on speech of consecutive patients with Parkinson disease.","volume":"76","author":"Tripoliti","year":"2011","journal-title":"Neurology"},{"issue":"13","key":"noi240025r16","doi-asserted-by":"publisher","first-page":"e1395","DOI":"10.1212\/WNL.0000000000206771","article-title":"Prospective long-term follow-up of focused ultrasound unilateral subthalamotomy for Parkinson disease.","volume":"100","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"noi240025r17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40409-018-0142-2","article-title":"Introducing the CONSORT extension to pilot trials: enhancing the design, conduct and reporting of pilot or feasibility trials.","volume":"24","author":"Abbade","year":"2018","journal-title":"J Venom Anim Toxins Incl Trop Dis"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2818520\/jamaneurology_martnezfernndez_2024_oi_240025_1717440887.04417.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T11:11:50Z","timestamp":1718017910000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2818520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.1220","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}